Our current special focus is on identification and assessment of residual risk factors such as small, dense LDL and Remnant lipoproteins
RISKS OF CVD
See video of our special focus on identification and assessment of residual risk factors such as small, dense LDL and Remnant lipoproteins
71st AACC Annual Scientific Meeting & Clinical Lab Expo
Anaheim, CA USA
August 6 – 8, 2019
Denka Group to Construct a
New Manufacturing Facility
for Producing Influenza…
NEW PRODUCT HIGHLIGHT
Helicobacter pylori colonizes in human gastric mucosa and causes chronic gastritis. It is well established that progression of inflammation leads to gastric mucosal atrophy and gastric cancer. The International Agency for Research on Cancer has recognized that H. pylori is a cause of gastric cancer and that eradication of H.pylori is a preventive measure for gastric cancer.
Cardiovascular Disease Prediction
by Small, Dense LDL Cholesterol
Accurately measure small dense LDL on your Hitachi or other analyzer.
The s LDL-EX ”SEIKEN” assay quantitatively determines small, dense
low-dense lipoproteins (sdLDL), a subfraction of LDL associated with
an increased risk for cardiovascular disease (CVD).
Reputation for innovation and quality
Denka Seiken has been relied on for more than half a century
for social contribution based on Immune, Antibody and Cell
Meeting the needs of the 21st Century
As mankind evolves in this increasingly global environment,
we are committed to the control of infectious diseases – always
at the threshold of a new era.
Diverse solutions for human health
Not only a manufacturer of vaccines for human use, but
we offer varied product lines, services, and in-depth knowledge
to hospitals and clinics.
Denka Seiken possesses numerous
collaborative business connections
We are connected with the world-wide top ten diagnostic companies for a number of products including FDA-clearance for sales in the US.
We offer highly original products of excellent quality in a
variety of fields, including clinical chemistry, immunochemistry,
and infectious disease IVD reagents.
Total Commitment to R&D
Denka Seiken effectively utilizes resources through commitment
to R&D and enhances technological capabilities for the promotion